ONC (BeOne Medicines) Short-Term Debt: $191 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
79 GF Score
Price $348.27
GF Value $374.09
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines Short-Term Debt?

BeOne Medicines ONC +5.60% 79 Short-Term Debt is $191 Mil as of Jun. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $374.09 (Fairly Valued). The stock has 5 warning signs investors should review.

BeOne Medicines's Short-Term Debt for the quarter that ended in Jun. 2026 was $191 Mil.

BeOne Medicines's quarterly Short-Term Debt increased from Dec. 2025 ($57 Mil) to Mar. 2026 ($116 Mil) and increased from Mar. 2026 ($116 Mil) to Jun. 2026 ($191 Mil).

BeOne Medicines's annual Short-Term Debt increased from Dec. 2023 ($688 Mil) to Dec. 2024 ($852 Mil) but then declined from Dec. 2024 ($852 Mil) to Dec. 2025 ($57 Mil).

BeOne Medicines Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

BeOne Medicines Short-Term Debt Related Terms

BeOne Medicines Short-Term Debt Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Short-Term Debt Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 427.57 328.97 688.37 851.53 57.29

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 808.39 813.30 57.29 116.14 190.90
ONC
79GF Score
BeOne Medicines Ltd ONC
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $191 Mil mean?
BeOne Medicines (ONC) has a Short-Term Debt of $191 Mil as of Jun. 2026.
Is BeOne Medicines' Short-Term Debt too high?
BeOne Medicines' current Short-Term Debt is $191 Mil. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Short-Term Debt compare to ALNY and RVMD?
BeOne Medicines' Short-Term Debt of $191 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. BeOne Medicines's current Short-Term Debt is $191 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $374.09, compared to a current price of $348.27 — trading 6.9% below its estimated fair value. The current Short-Term Debt is $191 Mil. BeOne Medicines' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Short-Term Debt is $191 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $348.27 is trading 6.9% below its estimated GF Value™ of $374.09. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for ONC:

  • Short-Term Debt: $191 Mil
  • GF Value™: $374.09 vs. price of $348.27 (6.9% below fair value)
  • GF Score™: 79/100 with 5 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$348.27
Price
$374.09
GF Value